Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Nadifloxacin→

Nadifloxacin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
124858-35-1
Molecular formula
C19H21FN2O4
Molecular weight
360.4 g/mol
Drug class
Topical fluoroquinolone antibacterialDNA gyrase and topoisomerase IV inhibitor
Mechanism of action
Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. It has activity against a range of Gram-positive and Gram-negative skin pathogens, including Cutibacterium acnes and Staphylococcus aureus.
Indications / reported uses
  • Topical treatment of acne vulgaris and selected superficial bacterial skin infections caused by susceptible organisms in markets where nadifloxacin is authorised.

Sources: https://www.tandfonline.com/doi/full/10.1586/17469872.1.5.643 · https://bertin-bioreagent.cvmh.fr/nadifloxacin/ · https://daneenpharma.com/nadif/ · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Topical fluoroquinolone antibacterial; DNA gyrase and topoisomerase IV inhibitor

Mechanism of action

Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. It has activity against a range of Gram-positive and Gram-negative skin pathogens, including Cutibacterium acnes and Staphylococcus aureus.

General use cases

  • Topical treatment of acne vulgaris and selected superficial bacterial skin infections caused by susceptible organisms in markets where nadifloxacin is authorised.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Nadifloxacin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nadifloxacin Permitted Daily Exposure (PDE) report (the Nadifloxacin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nadifloxacin Occupational Exposure Limit (OEL) report (the Nadifloxacin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.